Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Esha A Gangolli"'
Autor:
Scott Daigle, David Ciccone, Samantha Carreiro, Christine Loh, Neelu Kaila, Fu-Shan Kuo, Scott Boiko, Gene Yau, Esha A Gangolli, Denise Levasseur, Bhaskar Srivastava, Frank G Basile
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/d7116d7f7b804a0885f65ce7d1bf0e25
Autor:
Scott Daigle, Sunil Sharma, Xinyan Zhang, Martin Gutierrez, Patricia Fraser, David Sommerhalder, Scott Boiko, Esha A Gangolli, Bhaskar Srivastava, Frank G Basile, Marcus Noel, Amanda Hoerres, Nawaid Rana, Rama Balaraman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/eeeb277cba37407485a3b247289a090b
Autor:
Seung Tae Kim, Sujin Lee, Minhwa Park, Se Hoon Park, Joon Oh Park, Ho Yeong Lim, Young Suk Park, Won Ki Kang, Esha A. Gangolli, Hyeongchan Shin, Kyoung-Mee Kim, Simon J. Hollingsworth, Peter G.S. Mortimer, Jeeyun Lee
Publikováno v:
Translational Oncology, Vol 12, Iss 4, Pp 597-601 (2019)
MET amplification is a frequently observed genomic aberration in solid tumors. We conducted a phase I trial to evaluate dose-limiting toxicity (DLT) and recommended phase II dose (RP2D) for the combination therapy. The following dose levels were test
Externí odkaz:
https://doaj.org/article/b406b35b84a64e659486a5ba09d5da21
Autor:
Aleksandra Markovets, Kyung Kim, Barrett Nuttall, J. Carl Barrett, Simon J. Hollingsworth, Jung Yong Hong, Jeeyun Lee, Se Hoon Park, Kyoung-Mee Kim, Esha A. Gangolli, Seung Tae Kim, Peter G. Mortimer, Melanie M. Frigault
Publikováno v:
JCO Precision Oncology. :222-232
PURPOSE Some gastric cancers harbor MET gene amplifications that can be targeted by selective MET inhibitors to achieve tumor responses, but resistance eventually develops. Savolitinib, a selective MET inhibitor, is beneficial for treating patients w
Autor:
Melanie M, Frigault, Aleksandra, Markovets, Barrett, Nuttall, Kyoung-Mee, Kim, Se Hoon, Park, Esha A, Gangolli, Peter G S, Mortimer, Simon J, Hollingsworth, Jung Yong, Hong, Kyung, Kim, Seung Tae, Kim, J Carl, Barrett, Jeeyun, Lee
Publikováno v:
JCO Precision Oncology
PURPOSE Some gastric cancers harbor MET gene amplifications that can be targeted by selective MET inhibitors to achieve tumor responses, but resistance eventually develops. Savolitinib, a selective MET inhibitor, is beneficial for treating patients w
Autor:
Arpit Rao, David L. Morris, Vasileios Assikis, Jim J. Xiao, Adriel-John Ablaza, Andrea Loehr, Charles J. Ryan, Gautam Jha, Jenn Habeck, Esha A. Gangolli
Publikováno v:
Cancer Research. 81:445-445
Background: Rucaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), is approved in the US as monotherapy for patients (pts) with BRCA1/2-mutated mCRPC after androgen receptor (AR)-directed therapy and a taxane. Synthetic lethality has been observ
Autor:
Johann S. de Bono, Maura Rossetti, Jean-Pascal Machiels, Noémie Wald, Esha A. Gangolli, Joanne Lager, Erol Wiegert, Thubeena Manickavasagar, Nicola McIntyre, Chiara Martinoli, Ariane Migeotte, Laurence Buisseret, Sylvie Rottey, Brant Delafontaine
Publikováno v:
Journal of Clinical Oncology. 39:2562-2562
2562 Background: Tumors produce high levels of extracellular adenosine which suppress anti-tumor immune responses. Blocking A2A receptors, predominantly expressed on tumor-infiltrating immune cells, can reverse the immunosuppressive effect of adenosi
Autor:
Jim J. Xiao, Charles J. Ryan, Andrea Loehr, David L. Morris, Esha A. Gangolli, Jenn Habeck, Arpit Rao, Gautam Jha, Vasily J. Assikis, Adriel-John Ablaza
Publikováno v:
Journal of Clinical Oncology. 39:79-79
79 Background: Rucaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), is approved in the US as monotherapy for BRCA1/2 mutated mCRPC that has been treated with androgen receptor (AR)-directed therapy and a taxane. In previous studies, synthetic
Autor:
Kimberly A. Burton, Anita Narula, G. Stanley McKnight, Rejean L. Idzerda, Mouna Belyamani, Esha A. Gangolli, Michael D. Uhler, Sara J. Muchinsky
Publikováno v:
Molecular and Cellular Biology. 20:3442-3448
Protein kinase inhibitor (PKI) is a potent endogenous inhibitor of the cyclic AMP (cAMP)-dependent protein kinase (PKA). It functions by binding the free catalytic (C) subunit with a high affinity and is also known to export nuclear C subunit to the
Publikováno v:
The Journal of Steroid Biochemistry and Molecular Biology. 61:1-9
The human neuroblastoma cell line SK-N-SH has been used as a model system to study the interactions of the human estrogen receptor (hER) with neurotransmitters. We have successfully transfected these cells using an adenoviral delivery system and have